Effect of chemotherapy on urinary volatile biomarkers for lung cancer by HS-SPME-GC-MS and chemometrics.
2-pentanone
adenocarcinoma
biomarker
chemotherapy
lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
revised:
23
10
2023
received:
28
09
2023
accepted:
25
10
2023
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
aheadofprint
Résumé
Volatile organic compounds (VOCs) have been studied as possible biomarkers in several diseases, including lung cancer. Early detection of cancer can improve long-term survival rates and the quality of life, so the study of VOCs in exhaled breath and urine has been increasing in recent years. This study aimed to assess the urinary VOCs that are modified after chemotherapy to identify those with the potential to be lung cancer biomarkers that can be monitored during treatment. Three urine samples from 10 men with stage IV lung adenocarcinoma were collected, as well as urine samples from 14 men with other types of cancer (control group). All samples were analyzed by headspace-solid phase microextraction gas chromatography coupled with mass spectrometry. A total of 21 urinary VOCs were found with different levels after the administration of chemotherapy, with 2-pentanone being one of those that significantly decreased. Furthermore, 2-pentanone and 3-hydroxy-2,4,4-trimethylpentyl-2-methylpropanoate showed statistically significant differences with the control group. Chemotherapy administered to patients with advanced lung adenocarcinoma modified the volatile profile of urine. 2-Pentanone, a final product of the increased rate of fatty acid oxidation and protein hypermetabolism, significantly decreased after chemotherapy. Therefore, monitoring its urinary excretion could be very useful since its decrease over time could indicate an adequate response to chemotherapy and arrest of cancer development. Another VOC that could be a potential lung cancer biomarker is 3 hydroxy-2,4,4-trimethylpentyl-2-methylpropanoate, whose origin may be due to inhibition of the propanoic acid metabolic pathway or increased aldehyde dehydrogenase activity.
Sections du résumé
BACKGROUND
BACKGROUND
Volatile organic compounds (VOCs) have been studied as possible biomarkers in several diseases, including lung cancer. Early detection of cancer can improve long-term survival rates and the quality of life, so the study of VOCs in exhaled breath and urine has been increasing in recent years. This study aimed to assess the urinary VOCs that are modified after chemotherapy to identify those with the potential to be lung cancer biomarkers that can be monitored during treatment.
METHODS
METHODS
Three urine samples from 10 men with stage IV lung adenocarcinoma were collected, as well as urine samples from 14 men with other types of cancer (control group). All samples were analyzed by headspace-solid phase microextraction gas chromatography coupled with mass spectrometry.
RESULTS
RESULTS
A total of 21 urinary VOCs were found with different levels after the administration of chemotherapy, with 2-pentanone being one of those that significantly decreased. Furthermore, 2-pentanone and 3-hydroxy-2,4,4-trimethylpentyl-2-methylpropanoate showed statistically significant differences with the control group.
CONCLUSIONS
CONCLUSIONS
Chemotherapy administered to patients with advanced lung adenocarcinoma modified the volatile profile of urine. 2-Pentanone, a final product of the increased rate of fatty acid oxidation and protein hypermetabolism, significantly decreased after chemotherapy. Therefore, monitoring its urinary excretion could be very useful since its decrease over time could indicate an adequate response to chemotherapy and arrest of cancer development. Another VOC that could be a potential lung cancer biomarker is 3 hydroxy-2,4,4-trimethylpentyl-2-methylpropanoate, whose origin may be due to inhibition of the propanoic acid metabolic pathway or increased aldehyde dehydrogenase activity.
Identifiants
pubmed: 37945317
doi: 10.1111/1759-7714.15154
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778-789.
Blandin S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.
Duffy MJ, O'Byrne K. Tissue and blood biomarkers in lung cancer: a review. Adv Clin Chem. 2018;86:1-21.
Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17-33.
Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8.
Song G, Qin T, Liu H, Xu GB, Pan YY, Xiong FX, et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer. 2010;67(2):227-231.
Hanai Y, Shimono K, Matsumura K, Vachani A, Albelda S, Yamazaki K, et al. Urinary volatile compounds as biomarkers for lung cancer. Biosci Biotechnol Biochem. 2012;76(4):679-684.
Janssens E, van Meerbeeck JP, Lamote K. Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review. Crit Rev Oncol Hematol. 2020;153:103037.
Chen X, Muhammad KG, Madeeha C, Fu W, Xu L, Hu Y, et al. Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection. Lung Cancer. 2021;154:197-205.
Gasparri R, Capuano R, Guaglio A, Caminiti V, Canini F, Catini A, et al. Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer. J Breath Res. 2022;16(4):46008.
Mazzone PJ, Wang XF, Lim S, Choi H, Jett J, Vachani A, et al. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer. BMC Cancer. 2015;15:1001.
Taunk K, Porto-Figueira P, Pereira JAM, Taware R, da Costa NL, Barbosa R, et al. Urinary volatomic expression pattern: paving the way for identification of potential candidate biosignatures for lung cancer. Metabolites. 2022;12(1):36.
Feil C, Staib F, Berger MR, Stein T, Schmidtmann I, Forster A, et al. Sniffer dogs can identify lung cancer patients from breath and urine samples. BMC Cancer. 2021;21(1):917.
Ramos ÁG, Antón AP, Sánchez MDN, Pavón JLP, Cordero BM. Urinary volatile fingerprint based on mass spectrometry for the discrimination of patients with lung cancer and controls. Talanta. 2017;174:158-164.
Porto-Figueira P, Pereira J, Miekisch W, Câmara JS. Exploring the potential of NTME/GC-MS, in the establishment of urinary volatomic profiles. Lung cancer patients as case study. Sci Rep. 2018;8(1):13113.
Mohamed EI, Mohamed MA, Abdel-Mageed SM, Abdel-Mohdy TS, Badawi MI, Darwish SH. Volatile organic compounds of biofluids for detecting lung cancer by an electronic nose based on artificial neural network. J Appl Biomed. 2019;17(1):67.
Rubio-Sánchez R, Ríos-Reina R, Ubeda C. Identification of volatile biomarkers of trichomonas vaginalis infection in vaginal discharge and urine. Appl Microbiol Biotechnol. 2023;107:3057-3069.
Johnsen LG, Skou PB, Khakimov B, Bro R. Gas chromatography - mass spectrometry data processing made easy. J Chromatogr A. 2017;1503:57-64.
Mehmood T, Bohlin J, Kristoffersen AB, Saebø S, Warringer J, Snipen L. Exploration of multivariate analysis in microbial coding sequence modeling. BMC Bioinformatics. 2012;13:97.
Orywal K, Szmitkowski M. Alcohol dehydrogenase and aldehyde dehydrogenase in malignant neoplasms. Clin Exp Med. 2017;17(2):131-139.
Pérez A, Ramos ÁG, Del Nogal M, Pavón JL, Cordero BM, Pozas ÁP. Headspace-programmed temperature vaporization-mass spectrometry for the rapid determination of possible volatile biomarkers of lung cancer in urine. Anal Bioanal Chem. 2016;408(19):5239-5246.
Santos PM, Del Nogal M, Pozas ÁPC, Pavón JLP, Cordero BM. Determination of ketones and ethyl acetate-a preliminary study for the discrimination of patients with lung cancer. Anal Bioanal Chem. 2017;409(24):5689-5696.
Wang C, Dong R, Wang X, Lian A, Chi C, Ke C, et al. Exhaled volatile organic compounds as lung cancer biomarkers during one-lung ventilation. Sci Rep. 2014;4:7312.